A large collection of conserved eukaryotic peptidyl-prolyl cis-trans isomerases. Some members of this group are secreted (into the ER).. Localization: Cytoplasmic (by homology) / ER (by homology)
Chaperone/Protein Folding, cyclophilin 12 CYP12
Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 15 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 32 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 25 |
NetGPI | no | yes: 0, no: 25 |
Term | Name | Level | Count |
---|---|---|---|
GO:0016020 | membrane | 2 | 2 |
GO:0110165 | cellular anatomical entity | 1 | 6 |
GO:0005737 | cytoplasm | 2 | 4 |
GO:0005930 | axoneme | 2 | 1 |
GO:0031974 | membrane-enclosed lumen | 2 | 1 |
GO:0031981 | nuclear lumen | 5 | 1 |
GO:0032838 | plasma membrane bounded cell projection cytoplasm | 4 | 1 |
GO:0043233 | organelle lumen | 3 | 1 |
GO:0070013 | intracellular organelle lumen | 4 | 1 |
GO:0097014 | ciliary plasm | 5 | 1 |
GO:0099568 | cytoplasmic region | 3 | 1 |
Related structures:
AlphaFold database: A0A451EJ79
Term | Name | Level | Count |
---|---|---|---|
GO:0000413 | protein peptidyl-prolyl isomerization | 7 | 26 |
GO:0006807 | nitrogen compound metabolic process | 2 | 26 |
GO:0008152 | metabolic process | 1 | 26 |
GO:0018193 | peptidyl-amino acid modification | 5 | 26 |
GO:0018208 | peptidyl-proline modification | 6 | 26 |
GO:0019538 | protein metabolic process | 3 | 26 |
GO:0036211 | protein modification process | 4 | 26 |
GO:0043170 | macromolecule metabolic process | 3 | 26 |
GO:0043412 | macromolecule modification | 4 | 26 |
GO:0044238 | primary metabolic process | 2 | 26 |
GO:0071704 | organic substance metabolic process | 2 | 26 |
GO:1901564 | organonitrogen compound metabolic process | 3 | 26 |
GO:0006457 | protein folding | 2 | 13 |
GO:0009987 | cellular process | 1 | 13 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003755 | peptidyl-prolyl cis-trans isomerase activity | 3 | 26 |
GO:0003824 | catalytic activity | 1 | 26 |
GO:0016853 | isomerase activity | 2 | 26 |
GO:0016859 | cis-trans isomerase activity | 3 | 26 |
GO:0140096 | catalytic activity, acting on a protein | 2 | 26 |
GO:0005488 | binding | 1 | 3 |
GO:0016018 | cyclosporin A binding | 4 | 3 |
GO:0033218 | amide binding | 2 | 3 |
GO:0042277 | peptide binding | 3 | 3 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 220 | 224 | PF00656 | 0.217 |
CLV_NRD_NRD_1 | 51 | 53 | PF00675 | 0.357 |
CLV_PCSK_KEX2_1 | 51 | 53 | PF00082 | 0.355 |
CLV_PCSK_SKI1_1 | 105 | 109 | PF00082 | 0.431 |
CLV_PCSK_SKI1_1 | 140 | 144 | PF00082 | 0.408 |
CLV_PCSK_SKI1_1 | 2 | 6 | PF00082 | 0.321 |
CLV_PCSK_SKI1_1 | 219 | 223 | PF00082 | 0.368 |
CLV_Separin_Metazoa | 43 | 47 | PF03568 | 0.345 |
DEG_Nend_UBRbox_1 | 1 | 4 | PF02207 | 0.364 |
DOC_MAPK_gen_1 | 146 | 155 | PF00069 | 0.289 |
DOC_MAPK_MEF2A_6 | 148 | 157 | PF00069 | 0.285 |
DOC_PP1_RVXF_1 | 162 | 168 | PF00149 | 0.270 |
DOC_PP1_RVXF_1 | 288 | 295 | PF00149 | 0.312 |
DOC_PP2B_LxvP_1 | 42 | 45 | PF13499 | 0.330 |
DOC_PP4_FxxP_1 | 202 | 205 | PF00568 | 0.194 |
DOC_USP7_MATH_1 | 197 | 201 | PF00917 | 0.364 |
DOC_USP7_MATH_1 | 318 | 322 | PF00917 | 0.202 |
DOC_USP7_MATH_1 | 54 | 58 | PF00917 | 0.383 |
LIG_14-3-3_CanoR_1 | 105 | 113 | PF00244 | 0.498 |
LIG_14-3-3_CanoR_1 | 186 | 191 | PF00244 | 0.387 |
LIG_14-3-3_CanoR_1 | 282 | 287 | PF00244 | 0.269 |
LIG_BIR_III_4 | 258 | 262 | PF00653 | 0.218 |
LIG_BRCT_BRCA1_1 | 198 | 202 | PF00533 | 0.194 |
LIG_BRCT_BRCA1_1 | 273 | 277 | PF00533 | 0.415 |
LIG_FHA_1 | 250 | 256 | PF00498 | 0.343 |
LIG_FHA_2 | 116 | 122 | PF00498 | 0.463 |
LIG_FHA_2 | 12 | 18 | PF00498 | 0.501 |
LIG_FHA_2 | 218 | 224 | PF00498 | 0.248 |
LIG_FHA_2 | 323 | 329 | PF00498 | 0.291 |
LIG_LIR_Apic_2 | 199 | 205 | PF02991 | 0.202 |
LIG_LIR_Apic_2 | 250 | 256 | PF02991 | 0.277 |
LIG_LIR_Gen_1 | 168 | 176 | PF02991 | 0.304 |
LIG_LIR_Gen_1 | 275 | 284 | PF02991 | 0.258 |
LIG_LIR_Gen_1 | 34 | 44 | PF02991 | 0.318 |
LIG_LIR_Nem_3 | 137 | 142 | PF02991 | 0.305 |
LIG_LIR_Nem_3 | 168 | 173 | PF02991 | 0.365 |
LIG_LIR_Nem_3 | 215 | 221 | PF02991 | 0.241 |
LIG_LIR_Nem_3 | 275 | 281 | PF02991 | 0.399 |
LIG_LIR_Nem_3 | 34 | 39 | PF02991 | 0.308 |
LIG_LIR_Nem_3 | 5 | 10 | PF02991 | 0.372 |
LIG_PDZ_Class_1 | 329 | 334 | PF00595 | 0.353 |
LIG_Pex14_1 | 166 | 170 | PF04695 | 0.321 |
LIG_REV1ctd_RIR_1 | 215 | 223 | PF16727 | 0.207 |
LIG_SH2_CRK | 10 | 14 | PF00017 | 0.410 |
LIG_SH2_CRK | 170 | 174 | PF00017 | 0.235 |
LIG_SH2_CRK | 253 | 257 | PF00017 | 0.235 |
LIG_SH2_CRK | 36 | 40 | PF00017 | 0.283 |
LIG_SH2_NCK_1 | 170 | 174 | PF00017 | 0.217 |
LIG_SH2_PTP2 | 278 | 281 | PF00017 | 0.298 |
LIG_SH2_STAP1 | 170 | 174 | PF00017 | 0.218 |
LIG_SH2_STAP1 | 36 | 40 | PF00017 | 0.362 |
LIG_SH2_STAT3 | 131 | 134 | PF00017 | 0.312 |
LIG_SH2_STAT5 | 131 | 134 | PF00017 | 0.454 |
LIG_SH2_STAT5 | 150 | 153 | PF00017 | 0.274 |
LIG_SH2_STAT5 | 278 | 281 | PF00017 | 0.218 |
LIG_SH2_STAT5 | 291 | 294 | PF00017 | 0.218 |
LIG_SH3_3 | 198 | 204 | PF00018 | 0.336 |
LIG_TYR_ITSM | 6 | 13 | PF00017 | 0.380 |
LIG_WRC_WIRS_1 | 4 | 9 | PF05994 | 0.276 |
MOD_CK2_1 | 322 | 328 | PF00069 | 0.174 |
MOD_CK2_1 | 68 | 74 | PF00069 | 0.528 |
MOD_CK2_1 | 96 | 102 | PF00069 | 0.578 |
MOD_GlcNHglycan | 136 | 139 | PF01048 | 0.298 |
MOD_GlcNHglycan | 235 | 238 | PF01048 | 0.291 |
MOD_GlcNHglycan | 274 | 277 | PF01048 | 0.378 |
MOD_GlcNHglycan | 56 | 59 | PF01048 | 0.437 |
MOD_GlcNHglycan | 74 | 77 | PF01048 | 0.450 |
MOD_GlcNHglycan | 82 | 85 | PF01048 | 0.476 |
MOD_GSK3_1 | 185 | 192 | PF00069 | 0.333 |
MOD_GSK3_1 | 213 | 220 | PF00069 | 0.256 |
MOD_GSK3_1 | 229 | 236 | PF00069 | 0.383 |
MOD_GSK3_1 | 318 | 325 | PF00069 | 0.408 |
MOD_GSK3_1 | 68 | 75 | PF00069 | 0.732 |
MOD_N-GLC_1 | 272 | 277 | PF02516 | 0.312 |
MOD_N-GLC_2 | 180 | 182 | PF02516 | 0.272 |
MOD_NEK2_1 | 142 | 147 | PF00069 | 0.492 |
MOD_NEK2_1 | 169 | 174 | PF00069 | 0.257 |
MOD_NEK2_1 | 217 | 222 | PF00069 | 0.290 |
MOD_NEK2_1 | 277 | 282 | PF00069 | 0.291 |
MOD_NEK2_1 | 72 | 77 | PF00069 | 0.763 |
MOD_NEK2_2 | 197 | 202 | PF00069 | 0.202 |
MOD_NEK2_2 | 239 | 244 | PF00069 | 0.303 |
MOD_PIKK_1 | 204 | 210 | PF00454 | 0.349 |
MOD_PIKK_1 | 60 | 66 | PF00454 | 0.458 |
MOD_PKA_2 | 185 | 191 | PF00069 | 0.398 |
MOD_Plk_1 | 153 | 159 | PF00069 | 0.288 |
MOD_Plk_1 | 249 | 255 | PF00069 | 0.284 |
MOD_Plk_1 | 272 | 278 | PF00069 | 0.186 |
MOD_Plk_1 | 68 | 74 | PF00069 | 0.677 |
MOD_Plk_4 | 108 | 114 | PF00069 | 0.299 |
MOD_Plk_4 | 197 | 203 | PF00069 | 0.327 |
MOD_Plk_4 | 213 | 219 | PF00069 | 0.175 |
MOD_Plk_4 | 282 | 288 | PF00069 | 0.236 |
MOD_Plk_4 | 318 | 324 | PF00069 | 0.269 |
MOD_Plk_4 | 88 | 94 | PF00069 | 0.318 |
MOD_SUMO_for_1 | 40 | 43 | PF00179 | 0.495 |
TRG_DiLeu_BaEn_1 | 102 | 107 | PF01217 | 0.368 |
TRG_DiLeu_LyEn_5 | 102 | 107 | PF01217 | 0.348 |
TRG_ENDOCYTIC_2 | 10 | 13 | PF00928 | 0.397 |
TRG_ENDOCYTIC_2 | 150 | 153 | PF00928 | 0.253 |
TRG_ENDOCYTIC_2 | 170 | 173 | PF00928 | 0.218 |
TRG_ENDOCYTIC_2 | 278 | 281 | PF00928 | 0.218 |
TRG_ENDOCYTIC_2 | 291 | 294 | PF00928 | 0.284 |
TRG_ENDOCYTIC_2 | 36 | 39 | PF00928 | 0.301 |
TRG_Pf-PMV_PEXEL_1 | 105 | 110 | PF00026 | 0.332 |
TRG_Pf-PMV_PEXEL_1 | 219 | 223 | PF00026 | 0.333 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1IL84 | Leptomonas seymouri | 55% | 100% |
A0A0N1PDY0 | Leptomonas seymouri | 24% | 100% |
A0A0S4IKA5 | Bodo saltans | 39% | 100% |
A0A3Q8ICB3 | Leishmania donovani | 29% | 100% |
A0A3R7M7E5 | Trypanosoma rangeli | 43% | 100% |
A0A3S5H7U6 | Leishmania donovani | 38% | 100% |
A0A3S5IQL2 | Trypanosoma rangeli | 27% | 100% |
A0A3S7X325 | Leishmania donovani | 25% | 100% |
A0A3S7X410 | Leishmania donovani | 36% | 100% |
A0A3S7XB52 | Leishmania donovani | 34% | 100% |
A4H346 | Leishmania braziliensis | 83% | 100% |
A4HCI8 | Leishmania braziliensis | 28% | 100% |
A4HHU7 | Leishmania braziliensis | 24% | 100% |
A4HIW9 | Leishmania braziliensis | 35% | 100% |
A4HRE3 | Leishmania infantum | 100% | 100% |
A4I004 | Leishmania infantum | 29% | 100% |
A4I4Z7 | Leishmania infantum | 25% | 100% |
A4I698 | Leishmania infantum | 36% | 100% |
A4I935 | Leishmania infantum | 38% | 100% |
A4IDA1 | Leishmania infantum | 34% | 100% |
C9ZXF5 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 33% | 100% |
E9AC11 | Leishmania major | 94% | 100% |
E9AJA8 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 90% | 100% |
E9AT91 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 34% | 100% |
E9AVX7 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 29% | 100% |
E9B0C7 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 26% | 100% |
E9B1F3 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 36% | 100% |
E9B400 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 38% | 100% |
Q4Q1A6 | Leishmania major | 34% | 100% |
Q4Q6Q9 | Leishmania major | 36% | 100% |
Q4Q7V7 | Leishmania major | 26% | 100% |
Q4QBK2 | Leishmania major | 29% | 100% |
Q8IXY8 | Homo sapiens | 29% | 100% |
V5B9Y6 | Trypanosoma cruzi | 42% | 100% |